Internal Reference Number: FOI_7245
Date Request Received: 16/06/2023 00:00:00
Date Request Replied To: 04/07/2023 00:00:00
This response was sent via: By Email
Request Summary: lung cancer
Request Category: Companies
| Question Number 1: How many patients has your Trust treated in the past 3 months for: • Non-small cell lung cancer (NSCLC) - any treatment • Non-small cell lung cancer (NSCLC) - surgical treatment • Non-small cell lung cancer (NSCLC) - radiotherapy • Non-small cell lung cancer (NSCLC) - systemic anti-cancer treatment (SACT) | |
| Answer To Question 1: How many patients has your Trust treated in the past 3 months for: Data provided for March 23 - May 23 inc • Non-small cell lung cancer (NSCLC) - any treatment - 0 • Non-small cell lung cancer (NSCLC) - surgical treatment - 0 • Non-small cell lung cancer (NSCLC) - radiotherapy - <5 • Non-small cell lung cancer (NSCLC) - systemic anti-cancer treatment (SACT) - 37 | |
| Question Number 2: - How many Non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with: • ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib) • Amivantamab • Atezolizumab monotherapy • Atezolizumab with chemotherapy • Dabrafenib + Trametinib • Durvalumab • Gemcitabine • Nitendanib + Docetaxel • Nivolumab • Osimertinib • Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib) • Paclitaxel • Pembrolizumab monotherapy • Pembrolizumab with chemotherapy • Pemetrexed with carboplatin/cisplatin • RET Inhibitors (Pralsetinib, Selpercatinib) • Sotorasib • Tepotinib • Vinorelbine monotherapy or combination with Carboplatin/Cisplatin • Other active systemic anti-cancer therapy [please state] • Palliative care only | |
| Answer To Question 2: Data provided for March 23 - May 23 inc • ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib) 6 • Amivantamab 0 • Atezolizumab monotherapy 0 • Atezolizumab with chemotherapy 0 • Dabrafenib + Trametinib <5 • Durvalumab 5 • Gemcitabine 0 • Nitendanib + Docetaxel <5 • Nivolumab 0 • Osimertinib 9 • Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib) <5 • Paclitaxel 0 • Pembrolizumab monotherapy 6 • Pembrolizumab with chemotherapy <5 • Pemetrexed with carboplatin/cisplatin <5 • RET Inhibitors (Pralsetinib, Selpercatinib) 0 • Sotorasib <5 • Tepotinib 0 • Vinorelbine monotherapy or combination with Carboplatin/Cisplatin <5 • Other active systemic anti-cancer therapy [please state] docetaxel <5 • Palliative care only - Unable to answer | |
| Question Number 3: Of the NSCLC patients treated with Nivolumab in the past 3 months, how many patients received (surgery) or are scheduled to receive surgical treatment after commencement of the treatment with Nivolumab? | |
| Answer To Question 3: Data provided for March 23 - May 23 inc 0 | |
| To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
